New Study Highlights Adverse Effect on Neurocognitive Tests in Military Population

SILVER SPRING, Md. – A first-of-its-kind study of active-duty military using DANATM, a mobile, neurocognitive assessment tool, found that scores on self-administrated psychological assessments had a negative impact on a variety of neurocognitive tests. The study, “Computerized cognitive testing norms in active-duty military personnel: Potential for contamination by psychologically unhealthy individuals,” published in Applied Neuropsychology: Adult, suggests that effects of the increased incidence of behavioral health issues in active-duty military should be controlled for when determining normative datasets in this population. Researchers administered DANATM to 808 active-duty service members, ages 18-64 with 71 percent being male. Study participants self-administered three clinical psychological assessments ― Posttraumatic Stress Disorder Checklist-Military (PCL-M), the Patient Health Questionnaire 8 (PHQ-8) to assess depression, and the Pittsburgh Sleep Quality Index (PSQI). The researchers then examined performance on eight cognitive tests to evaluate the effect of self-reported sleep disturbance, depression and Post-Traumatic Stress Disorder (PTSD). “PTSD, depression, and disturbed sleep are common psychological issues affecting military personnel,” said AnthroTronix CEO Cori Lathan. “What we found was a direct negative impact on cognitive function when study participants self-reported these issues. These factors may distort normative data in this population and should be considered along with basic demographic characteristics.” Results showed that 13 percent of participants scored within clinical range on the PCL-M (score ≥34 for “moderate PTS”), six percent within clinical range on the PHQ-8 (score ≥10 for “major depression”), and 48 percent within clinical range on the PSQI (score ≥5 for “poor sleep quality”). Researchers observed that PCL-M scores were also negatively associated with performance on many neurocognitive tests and associations among PCL-M, PHQ-8, and PSQI scores....

AnthroTronix and Nview Health Collaboration Powers Seamless Assessment of Cognition and Behavioral Health

AnthroTronix and Nview Health Collaboration Powers Seamless Assessment of Cognition and Behavioral Health — Provides Consistent Measurement of Cognitive and Behavioral Health in One Place — SILVER SPRING, Md. – AnthroTronix and Nview Health announced today they have partnered to combine two technologies to test both a person’s cognitive function and their behavioral health. Used together, these technologies can provide healthcare practitioners with better insight into a person’s complete behavioral health and wellness. AnthroTronix’s DANA TM is an FDA cleared clinical neurocognitive assessment tool that uses a smartphone or tablet to measure and monitor changes in a person’s brain/cognitive function. The app can help clinicians track cognitive function for conditions such as depression, dementia/Alzheimer’s Disease, and Post-Traumatic Stress Disorder. “Cognitive function and behavioral health are closely linked,” said AnthroTronix CEO Cori Lathan. “Our behavioral health status effects our cognitive efficiency so to get a clear picture of a person’s brain health, it’s important to test both. Our partnership with Nview Health now enables healthcare providers the ability to do that.” Nview’s diagnostic instrument, the M.I.N.I. — Mini International Neuropsychiatric Interview — is a short, structured diagnostic interview designed to evaluate the most common DSM-5 and ICD-10 psychiatric disorders. It enables healthcare professionals to rapidly deliver a behavioral health diagnosis and has been used in patient care and clinical research for more than 25 years. “Our partnership with AnthroTronix now allows us to measure an individual’s cognitive status, which is essential to the care and treatment of behavioral health disorders,” said Nview Health Chief Executive Officer and Co-Founder Thomas R. Young, M.D. ### About AnthroTronix AnthroTronix, an engineering research and development company, produces human-centered technologies that advance health, communication, education, and defense. We...

Health-eBrain Study to Launch Phase II

Health-eBrain Study to Launch Phase II Mobile Platform Captures and Analyzes Cognitive and Emotional Health of Caregivers of Alzheimer’s Patients Toronto – BrightFocus Foundation, Geoffrey Beene Foundation Alzheimer’s Initiative, AnthroTronix, and Mindoula, have launched Phase II of the Health-eBrain Study, investigating the impact the Alzheimer’s caregiving experience has on brain and behavioral health. The announcement will be made at the Global Alliance for Women’s Brain Health Luncheon at the Alzheimer’s Association International Conference in Toronto on July 26, 2016. More than 1,000 caregivers were recruited for Phase I of the study, which documented cognitive impairment in the informal caregiver population compared with matched controls. An informal caregiver is defined as an unpaid person without formal training, such as a family member, who provides care for an individual with dementia. “Given the results we found in Phase I, we have set two goals for Phase II. The first is to look at caregiver stressors that could be possible causes for this cognitive impairment as well as provide an intervention that could help these caregivers with their mental health,” said Dr. Cori Lathan, board chair and CEO of AnthroTronix. “The rigor of science can help us better understand and improve caregivers’ health,” said BrightFocus President and CEO Stacy Pagos Haller. “BrightFocus is honored to support such innovative research.” In Phase II, an international cohort of caregivers will use DANATM, AnthroTronix’s FDA-cleared brain health assessment mobile app, to assess their cognitive function over 12 weeks. DANA provides detailed feedback about brain function that can be analyzed for changes over time. All participants in Phase II will use DANA, with some participants also using Mindoula. DANA will track...

AnthroTronix CEO to Conduct Davos Brain Challenge and Discuss Technology and the Brain at the Annual Meeting of the New Champions

WHO:   AnthroTronix (@AnthroTronix), a leader in digital health technology and engineering research and development committed to optimizing the interaction between people and technology. WHAT: At the World Economic Forum’s Annual Meeting of the New Champions, AnthroTronix CEO Dr. Cori Lathan (@clathan) will conduct the Davos Brain Challenge using its FDA-cleared DANA brain health assessment app. AnthroTronix held a similar exhibit at the World Economic Forum Annual Meeting in Davos-Klosters, Switzerland, earlier this year. AnthroTronix will invite attendees to assess their brain health and discover how innovative digital capabilities are transforming the way we assess and monitor our brain health. In addition, Dr. Lathan will discuss how digital technology, such as DANA, is improving our understanding of the brain and how we identify conditions and changes in cognitive function. Dr. Lathan has been named a Technology Pioneer and Young Global Leader by the World Economic Forum and is currently chair of their Global Agenda Council on Artificial Intelligence (AI) and Robotics. WHERE: Davos Brain Challenge Brain Hub, Works in Progress Exhibition Meijiang Convention & Exhibition Centre Tianjin, People’s Republic of China WHEN: June 26 – 28, 2016 Download PDF of press...

AnthroTronix and Cambridge Cognition have signed a distribution agreement to sell DANA, AnthroTronix’s FDA-cleared mobile brain health assessment app, to markets in the U.S. and Europe.

AnthroTronix and Cambridge Cognition Announce Distribution Agreement for Mobile Medical App Silver Spring, Md. – AnthroTronix and Cambridge Cognition Holdings PLC (Cambridge, UK – LSE: COG), have signed a distribution agreement to sell DANATM, AnthroTronix’s FDA-cleared mobile brain health assessment app, to markets in the U.S. and Europe. In the U.S., Cambridge Cognition will distribute DANA for use in academic research, clinical trials, and pharmaceutical development. In the United Kingdom and portions of Europe, DANA will be marketed for use in militaries, academic research, clinical trials, pharmaceutical development, and occupational health screenings. DANA, which was initially developed for use by the U.S. military to help evaluate the medical status of deployed service members, is a mobile medical app that administers game-like tests to assess a person’s brain/cognitive health within minutes. The app can help track cognitive function over time and during treatment for such conditions as depression, dementia/Alzheimer’s Disease, and Post-Traumatic Stress Disorder. DANA can be used on a phone or tablet and works on both the Android and iOS operating systems. “Brain health assessment is a fundamental part of an integrated approach to health care,” said Dr. Cori Lathan, @clathan, founder and CEO of AnthroTronix. “With this agreement, DANA has expanded its global reach and further establishes AnthroTronix as a leader in the growing brain and cognitive health assessment and training market, which is expected to surpass $6 billion worldwide by 2020.” “Having worked informally with AnthroTronix since 2015 we are confident that DANA fits within our existing point-of-care product portfolio and are excited by the opportunity to commercialize the product through established Cambridge Cognition sales channels to...